Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies

Abstract

Study objectiveTo summarize and compare efficacy of sugammadex with neostigmine or placebo for reversal of rocuronium- or vecuronium-induced neuromuscular blockade (NMB), and to demonstrate consistency of sugammadex results across various patient populations. DesignPooled analysis on data from 26 multicenter, randomized, Phase II and III studies. SettingOperating room. Patients1855 adults undergoing surgery under general anesthesia and receiving rocuronium or vecuronium for NMB. InterventionsSugammadex (2.0mg/kg at second twitch reappearance [T2; moderate NMB], 4.0mg/kg at 1–2 post-tetanic counts [PTC; deep NMB] or 16.0mg/kg at 3min after rocuronium 1.2mg/kg), neostigmine or placebo. MeasurementsTime to recovery of the train-of-four (TOF) ratio to 0.9. Main resultsGeometric mean (95% CI) times to recovery to TOF ratio of 0.9 were 1.9 (1.8–2.0) min following sugammadex 2.0mg/kg and 10.6 (9.8–11.6) min following neostigmine administration at T2 after rocuronium, and 2.9 (2.5–3.4) min and 17.4 (13.4–22.6) min, respectively, after vecuronium. Recovery times were 2.2 (2.1–2.3) min following sugammadex 4.0mg/kg and 19.0 (14.8–24.6) min following neostigmine administered at a target of 1–2 PTC after rocuronium, and 3.8 (3.0–5.0) min and 67.6 (56.3–81.2) min after vecuronium. Sugammadex administered 3min after rocuronium 1.2mg/kg resulted in rapid recovery (1.7 [1.5–2.0] min). Modest increases in mean recovery time were associated with vecuronium use (+1.6min [78%; (61%–98%)] versus rocuronium), mild-to-moderate renal impairment (+0.4min [20%; (9%–32%)] versus normal renal function) and geographic location (+1.0min [38%; (25%–52%)] in subjects in USA/Canada versus Europe/Japan). ConclusionsSugammadex administered at recommended doses provides rapid and predictable reversal of rocuronium and vecuronium-induced moderate and deep NMB, and effective reversal 3min after rocuronium 1.2mg/kg. Robust recovery was seen across various patient factors, providing further confirmation of labeled dose recommendations.